Long-term study of ALKS 2680 for narcolepsy and idiopathic hypersomnia
Tests ALKS 2680 tablets over time in adults with narcolepsy or idiopathic hypersomnia.
Key facts
- Who runs it
- Alkermes, Inc.
- Where
- Abington, Atlanta, Austin, Boulder, Brandon, Canton, Cincinnati, Colorado Springs, Columbia, Cullman, Dallas, Denver, Dublin, Huntersville, Kansas City, Lansing, Lincoln, Little Rock, Los Angeles, Macon, Madison, Miami, Middletown, Peoria, Phoenix, San Antonio, San Francisco, Stanford, Sterling Heights, Stockbridge, Sugar Land, Winter Park, and Wyomissing, United StatesSee the 33 sitesAlso in 7 other countries, 33 sites
- Trial code
- Registry title
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 786 people, planned
- Started
- 27 Jan 2025
- Expected to end
- Jun 2030
- Type of study
- Interventional, 3 groups
- Treatments tested
- ALKS 2680, 4mg
- ALKS 2680, 6mg
- ALKS 2680, 8mg
- ALKS 2680, 10mg
- ALKS 2680, 14mg
- ALKS 2680, 18mg
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with narcolepsy type 1, narcolepsy type 2 or idiopathic hypersomnia who finished an earlier ALKS 2680 study. They will keep taking ALKS 2680 tablets long term.
- Age
- 18 Years to 70 Years
- Sex
- All sexes can join.
- Disease stage
- Narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) or idiopathic hypersomnia (IH), an illness with too much daytime sleepiness.
- Earlier treatment
- People must have completed the end of treatment visit of an earlier ALKS 2680 study: ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2), ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1), ALKS 2680-303 (Brilliance NT2) or ALKS 2680-304 (Brilliance NT 1). They must be able to safely stop other narcolepsy medicines for 5 half-lives before Day 1 (for re-entry subjects) and during the whole study.
Main reasons for not taking part
- A new serious health problem, ECG or lab abnormality that may affect taking part
- Being pregnant, breastfeeding, or planning a pregnancy during the study
- Being in another clinical study, other than the earlier study
- Using any experimental drug or device within 30 days before screening
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1, NT2 or IH. The current eligible studies are ALKS 2680-201 (Vibrance-1), ALKS 2680-202 (Vibrance-2) and ALKS 2680-203 (Vibrance-3), ALKS 2680-302 (Brilliance NT1) , ALKS 2680-303 (Brilliance NT2) , ALKS 2680-304 (Brilliance NT 1)
- Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the duration of study (for all subjects)
Who cannot take part
- Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening
- Developed a new clinically significant health condition, ECG or laboratory abnormality, in the opinion of the Investigator or Sponsor, may impact the subject's participation in the study
- Is currently pregnant, breastfeeding, or planning to become pregnant during the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
Also in 7 other countries, 33 sites
- Abington, PennsylvaniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Atlanta, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Austin, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Boulder, ColoradoHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Brandon, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Canton, OhioHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Cincinnati, OhioHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Colorado Springs, ColoradoHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Columbia, South CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Cullman, AlabamaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Dallas, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Denver, North CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Dublin, OhioHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Huntersville, North CarolinaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Kansas City, KansasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Lansing, MichiganHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Lincoln, NebraskaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Little Rock, ArkansasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Los Angeles, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Macon, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Madison, WisconsinHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Miami, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Middletown, New JerseyHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Peoria, IllinoisHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Phoenix, ArizonaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- San Antonio, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- San Francisco, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Stanford, CaliforniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Sterling Heights, MichiganHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Stockbridge, GeorgiaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Sugar Land, TexasHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Winter Park, FloridaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
- Wyomissing, PennsylvaniaHospital not named in the registryContact: Director, Global Clinical ServicesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
The 3 groups in the trial
- Narcolepsy Type 1 (NT1)Treatment being tested
Treatment: ALKS 2680, 4mg, ALKS 2680, 6mg, and ALKS 2680, 8mg
- Narcolepsy Type 2 (NT2)Treatment being tested
Treatment: ALKS 2680, 10mg, ALKS 2680, 14mg, and ALKS 2680, 18mg
- Idiopathic Hypersomnia (IH)Treatment being tested
Treatment: ALKS 2680, 10mg, ALKS 2680, 14mg, and ALKS 2680, 18mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia
- Plain-language title
- Long-term study of ALKS 2680 for narcolepsy and idiopathic hypersomniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06767683, who can take part
- Record updated
- 9 October 2026